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Abstract
In humans, the aldehyde dehydrogenase superfamily consists of 19 isoenzymes which mostly 
catalyze the NAD(P)+-dependent oxidation of aldehydes. Many of these isoenzymes have 
overlapping substrate specificities and therefore their potential physiological functions may 
overlap. Thus the development of new isoenyzme-selective probes would be able to better 
delineate the function of a single isoenyzme and its individual contribution to the metabolism of a 
particular substrate. This specific study was designed to find a novel modulator of ALDH2, a 
mitochondrial ALDH isoenzyme most well-known for its role in acetaldehyde oxidation. 53 
compounds were initially identified to modulate the activity of ALDH2 by a high-throughput 
esterase screen from a library of 63,000 compounds. Of these initial 53 compounds, 12 were found 
to also modulate the oxidation of propionaldehyde by ALDH2. Single concentration 
measurements at 10 μM compound were performed using ALDH1A1, ALDH1A2, ALDH1A3, 
ALDH2, ALDH1B1, ALDH3A1, ALDH4A1, and/or ALDH5A1 to determine the selectivity of 
these 12 compounds towards ALDH2. Four of the twelve compounds shared an aromatic lactone 
structure and were found to be potent inhibitors of the ALDH1/2 isoenzymes, but have no 
inhibitory effect on ALDH3A1, ALDH4A1 or ALDH5A1. Two of the aromatic lactones show 
selectivity within the ALDH1/2 class, and one appears to be selective for ALDH2 compared to all 
other isoenzymes tested.
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1. Introduction
Aldehydes are found throughout the body as a product of dietary metabolism and the 
biotransformation of neurotransmitters, carbohydrates, lipids, and endogenous amino acids 
[1–3]. In addition numerous aldehydes are present in the environment in smog, motor 
vehicle exhaust, and formed during the production of plastics [4, 5]. The accumulation of 
aldehydes within the body can lead to cytotoxicity and carcinogenesis[3, 4, 6, 7]. The human 
body has multiple systems of enzymes to alleviate aldehyde stress, one of these being the 
aldehyde dehydrogenases (ALDHs). The human genome has 19 functional genetic loci for 
members of the ALDH superfamily, most of which catalyze the NAD(P)+-dependent 
oxidation of aldehydes to their respective carboxylic acids, except for ALDH6A1, which 
catalyzes the formation of their respective CoA esters[4, 8]. ALDHs are separated into 
families and subfamilies based on their sequence similarity[9]. The 19 ALDHs share similar 
but distinct functions within the body due to their varying substrate specificities and gene 
expression differences. Some gene products, such as ALDH1A1 and ALDH2, are 
ubiquitously expressed, whereas others are expressed preferentially in certain tissues or 
during certain periods of development. Naturally occurring mutations within various 
ALDHs cause human diseases or aversive conditions such as the alcohol flush reaction 
(ALDH2), Sjogren-Larsson syndrome (ALDH3A2), type II hyperprolinemia (ALDH4A1), 
and 4-hydroxybutyricaciduria (ALDH5A1) [10–12]. In contrast, members of the ALDH1 
and ALDH2 families possess broad and somewhat overlapping substrate specificities 
making specific assignment of function difficult. Due to the apparent overlap in their 
function, ALDH-selective chemical probes could aid in gaining a better understanding of the 
function of these ALDHs, especially those which are within the same family or subfamily.
For several years our lab has been interested in finding novel selective compounds for 
ALDH1A1, ALDH2, and ALDH3A1[13–15]. ALDH1A1 and ALDH3A1 are cytosolic 
proteins expressed in many cell types, including ocular tissues where they appear to function 
as corneal crystallins. Both ALDH1A1 and ALDH3A1 are implicated in providing 
resistance to certain anti-cancer agents, such as cyclophosphamide[16–18]. ALDH1B1, a 
mitochondrial enzyme most similar to ALDH2, has recently been shown to be a potential 
biomarker for colon cancer[19]. ALDH1A1, along with the related cytosolic isoenzymes 
ALDH1A2 and ALDH1A3, contribute to retinoid metabolism[20]. ALDH1A2 and 
ALDH1A3 perform crucial functions during embryogenesis, as individual genetic knockout 
of these two genes in mice are not viable[21, 22]. ALDH2 is a mitochondrial enzyme which 
is most well-known for its role in acetaldehyde metabolism[23]. However, other members of 
the ALDH family can contribute to acetaldehyde metabolism, especially when ALDH2 
activity is reduced by the presence of the ALDH2*2 allele[24]. These other isoenzymes 
include ALDH1B1 and ALDH1A1[25, 26]. ALDH2, along with ALDH1A1, is implicated in 
the metabolism of the neurotransmitter dopamine[27]. In addition to these oxidative 
functions, ALDH2 can contribute to cardiovascular function through its ability to bioactivate 
nitroglycerin by acting as a nitrate reductase, and has been associated with cardioprotection 
from ischemic damage by limiting the damage from lipid peroxidation products[28]. Many 
of the other isoenzymes in the ALDH1, ALDH2, and ALDH3 families are also known to 
have a cytoprotective role against lipid peroxidation products[1]. The discovery and 
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development of isoenzyme-selective inhibitors or activators could prove useful in evaluating 
the relative contributions that these related ALDH isoenzymes make toward these common 
substrates.
Here we report the results of a high-throughput screen designed to discover selective 
modulators of ALDH2 activity. The screen identified 53 compounds from a library of 63000 
compounds that modulated the esterase activity of ALDH2. Commercially available 
compounds were then tested for their effects on the oxidation of aldehyde substrate by 
ALDH1A1, ALDH1A2, ALDH1A3, ALDH2, ALDH1B1, ALDH3A1, ALDH4A1, and 
ALDH5A1. This screen discovered a set of four aromatic lactones which exhibit potent 
inhibition of the ALDH1/2 family members but do not inhibit ALDH3A1, ALDH4A1, or 
ALDH5A1 activity. Two compounds in particular show selectivity for ALDH2 versus 
ALDH1A1, and one of those two shows selectivity for ALDH2 versus all other tested 
isoenzymes. Future characterization will include determining the mechanism by which these 
aromatic lactones inhibit the ALDH1/2 family of isoenzymes.
2. Materials and Methods
2.1 Materials
All materials were purchased from Sigma-Aldrich, unless otherwise noted.
2.2 Expression of ALDH
ALDH1A1, ALDH1A2, ALDH1A3, ALDH2, ALDH1B1, ALDH3A1, ALDH4A1, and 
ALDH5A1 were prepared and purified as previously described [13, 15, 29, Morgan et al, 
Chemico-Biological Interactions (This issue)]
2.3 High-throughput Screening
63,000 compounds from ChemDiv were present in 20 μL aliquots in 2% DMSO at 25 μM 
concentration in 384 well plates. Primary screening was completed in 384 well clear bottom 
plates by measuring the increase in absorbance of para-nitrophenol at λ=405 nm (molar 
extinction coefficient of 18,000 M−1cm−1 in a 50 μL assay containing 75 nM ALDH2, 0.8 
mM para-nitrophenylacetate, 10 μM library compound, 2% DMSO, and 25 mM HEPES 
buffer, pH 7.5 on a Spectromax Plus 384 plate reader for 7 min. Additional wells on each 
plate either had 100 μM daidzin as a control inhibitor or no compound present to determine 
the normal rate. Compounds which showed greater than 35% inhibition or 1.3x activation 
compared to control reactions were then rescreened for validation. Compounds were cherry-
picked from the mother plate to perform the validation screening which used the same 
esterase assay as the primary screen. Compounds which showed greater than 25% inhibition 
or 1.25x activation in this second screen were chosen for further analysis.
2.4 ALDH2 Dehydrogenase Screen
Commercially available compounds validated from the esterase screen were purchased from 
ChemDiv, ChemBridge, Princeton BioMolecular Research, and InterBioScreen. Compounds 
were screened for their effect on the oxidation of propionaldehyde by ALDH2. The 
dehydrogenase activity was assayed spectrophotometrically on a Beckman DU-640 by 
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measuring the increase in absorbance of NAD(P)H at 340 nm (molar extinction coefficient 
of 6220 M−1cm−1) for 2–3 min. The assay included 200 μM NAD+, 100 μM 
propionaldehyde, 200 nM ALDH2, 1% DMSO, and 10 μM compound in 25 mM BES, pH 
7.5.
2.5 Selectivity Assays for Other ALDH Isoenzymes
Compounds which modulated the oxidation of propionaldehyde by ALDH2 were then tested 
for their effect on the oxidation of aldehyde substrate by ALDH1A1, ALDH1A2, 
ALDH1A3, ALDH1B1, ALDH3A1, ALDH4A1, and ALDH5A1. Compounds were initially 
tested for selectivity against ALDH1A1 and ALDH3A1. Compounds which were selective 
against these two isoenzymes were then tested against the other isoenzymes. The assay 
components for these selectivity assays were designed to provide the maximal stringency 
toward ALDH2 such that the substrate concentration utilized was >500-fold above KM for 
ALDH2 while keeping below 15- fold over KM for the other isoenzymes. The 
dehydrogenase activity was assayed spectrophotometrically on a Beckman DU-640 by 
measuring the increase in absorbance of NAD(P)H at 340 nm (molar extinction coefficient 
of 6220 M−1cm−1) for 2–3 min. For the other ALDH1A family members, the assays 
included 200 μM NAD+, 100 μM propionaldehyde (KM values ~ 50 μM for ALDH1A1 and 
ALDH1A2[30, 31] and KM value for ALDH1A3 determined empirically by varying 
propionaldehyde concentration), 100–200 nM enzyme, 1% DMSO, and 10 μM compound in 
25 mM BES, pH 7.5. The assay for ALDH1B1 included 500 μM NAD+ and 200 μM 
propionaldehyde (KM ~ 14 μM[32]). For ALDH4A1, the assay included 1.5 mM NAD+ and 
20 mM propionaldehyde (KM ~ 9 mM[33]). For ALDH5A1, the assay included 1.5 mM 
NAD+ and 2 mM propionaldehyde (KM ~ 600 μM[34]). For ALDH3A1, the assay included 
the commonly utilized substrate benzaldehyde at 300 μM (KM ~ 200 μM [35]), 300 μM 
NADP+, 20 nM ALDH3A1, 1% DMSO, and 10 μM compound. ALDH3A1, ALDH4A1, 
and ALDH5A1 also used 100 mM sodium phosphate buffer, pH 7.5.
2.6 Substrate Competition Assay
Steady-state kinetics were used to determine the mode of inhibition by varying inhibitor and 
substrate concentrations for the prototypical member of this inhibitor family; 2P4. 
Dehydrogenase activity was measured on a Cary Eclipse fluorimeter by monitoring the 
fluorescence of NADH at 470 nm after excitation at 320 nm for 2 min measuring every five 
seconds. Assay conditions included 5 nM ALDH2, 400 μM NAD+, 75–600 nM 
propionaldehyde, 0.2% DMSO, and 0–80 nM inhibitor in 100 mM NaPi, pH 7.0 in 3 mL 
reaction volume. The reaction was initiated by addition of substrate. Due to the low 
concentrations of substrate used in the assay, all reagents were filtered to remove additional 
aldehyde contaminants. A standard curve of the fluorescence of NADH from 10 nM to 3000 
nM was used to convert the arbitrary fluorescence units into the amount of NADH produced 
during the experiment. All data were fit to the tight binding non-linear velocity expressions 
for competitive, non-competitive, mixed-type non-competitive, and uncompetitive inhibition 
using SigmaPlot (v12, Enzyme Kinetics Module) to evaluate goodness of fit. Lineweaver-
Burk plots were generated using SigmaPlot to better visualize the mode of inhibition. All 
data represent the average of four independent experiments of duplicate assays at each 
concentration.
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3 Results and Discussion
3.1 High-throughput ALDH2 Esterase Screen
Primary screening identified 1495 compounds from a 63,000 compound library which either 
activated the esterase activity of ALDH2 at least 1.3-fold or inhibited it by at least 35%. Of 
these 1495 compounds, only 57 of them were identified as activators of the esterase activity. 
In the secondary screen, 53 compounds, 11 activators and 42 inhibitors, modulated the 
esterase activity of ALDH2 greater than 25%. Figure 1A depicts the primary screen results 
for these 53 hit compounds.
3.2 ALDH2 Dehydrogenase Screen
Out of the 53 lead compounds identified by the high-through esterase screen, 45 were 
commercially available. Compounds were ordered and initially tested for their effect at 10 
μM concentration on the oxidation of propionaldehyde by ALDH2 on a Beckman DU-640 
(Figure 1B). Several compounds showed no effect on the dehydrogenase activity of ALDH2 
at 10 μM despite exhibiting effects on the esterase activity in the high-throughput screen. 
However, eleven compounds did inhibit the oxidation of propionaldehyde by ALDH2 
>20%, and one activated the activity >20% (P0146I21).
3.3 Selectivity of Screening Compounds
Compounds which modulated the oxidation of propionaldehyde by ALDH2 >20% were then 
examined for their effects on the dehydrogenase activity of ALDH1A1 and ALDH3A1 
(Table 1). The relative concentrations of substrate used with ALDH1A1 (~2- to 5-fold over 
KM) and ALDH3A1 (~1.5-fold over KM) are low compared to the relative concentration of 
ALDH2 used (~500-fold > KM). Therefore, if a compound does modulate the activity of 
ALDH2 any effect on the other two isoenzymes should be easily measureable. Several of the 
compounds modulated the oxidation of aldehyde substrate by one or both ALDH1A1 and 
ALDH3A1. One compound activated the dehydrogenase activity of all three isoenzymes 
(P00146L21) and a different compound greatly inhibited the activity of all three isoenzymes 
(P0024N09), both showing a lack of selectivity for any one of the three isoenzymes. Three 
compounds showed selectivity for ALDH2 at 10 μM concentration (P0008L19, P0027H05, 
and P0038F16). However, a second batch of P0027H05 ordered after initial testing did not 
inhibit ALDH2 dehydrogenase activity at this concentration. Two other compounds 
identified by this screen were structurally similar to P0008L19 and P0038F16 (P0038B18 
and P0038D18).
3.4 Characterization of Aromatic Lactones
The four structurally similar compounds (P0008L19, methyl-2-[(4-methyl-2-oxo-2H-
chromen-7-yl)oxy]propanoate, 2BS4; P0038F16, 2,3,5,6-tetramethylfuro[3,2-g]chromen-7-
one, 2P4; P0038B18, 3,5-dimethyl-6-propylfuro[3,2-g]chromen-7-one, 2CB5; P0038D18, 
2,3,5-trimethyl-6-propyl-7H-furo[3,2-g]chromen-7-one, 2P3) are aromatic lactones (Figure 
2A). Three of them (2P3, 2P4, and 2CB5) share the same core three-ringed aromatic 
structure, differing only in the alkyl chains bound to the aromatic rings. The fourth, 2BS4, 
shares the two six-membered rings with the other three; however, in place of the furan ring 
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2BS4 has a short alkyl chain with a terminal ester group connected to the aromatic system 
via an ether linkage with the ether oxygen in the same position relative to the oxygen in the 
furan ring in the other three compounds. 2BS4 also lacks an alkyl chain proximal to the 
lactone carbonyl.
However, if this class of compounds demonstrates uncompetitive inhibition towards 
substrate the substrate concentration utilized (~500-fold > Km) for measuring ALDH2 
activity would actually enhance the inhibition relative to the other isoenzymes, since the 
substrate concentrations utilized in their assays were much closer to their respective Km 
values. To exclude this particular scenario, the mode of inhibition with respect to substrate 
binding for 2P4 was measured for ALDH2. The kinetic data for 2P4 inhibition when varying 
substrate best fit the tight binding mixed-type non-competitive mode of inhibition (Figure 
2B) with a Ki = 35 ±3 nM, propionaldehyde Km = 93 ±7 nM, and α= 2.1 ±0.3. This result 
supports our assay design where the assay for ALDH2 dehydrogenase activity is the most 
stringent of the isoenzymes with respect to the potential for inhibition.
In addition to the effect of the four aromatic lactones on the dehydrogenase activity of 
ALDH1A1, ALDH2, and ALDH3A1 previously measured, the lactones were tested for their 
effect on the oxidation of propionaldehyde by ALDH1A2, ALDH1A3, ALDH1B1, 
ALDH4A1, and ALDH5A1 at a concentration of 10 μM to determine their potency and 
selectivity for these various isoenzymes (Figure 2C). The substrate concentrations for the 
additional five isoenzymes used in these assays were between 2- and 14-fold in excess of 
their respective KM for propionaldehyde, considerably less than the ~500-fold above KM for 
propionaldehyde [36] used for ALDH2, making the ALDH2 inhibition assay the most 
stringent test compared to the other isoenzymes. Propionaldehyde was used as the common 
substrate between assays when possible, including the cases of ALDH4A1 and ALDH5A1 
where the preferred substrates of γ-glutamate semialdehyde (ALDH4A1) and succinic 
semialdehyde (ALDH5A1) were difficult to obtain. In our hands the approximate KM value 
for ALDH1A3 was ~15 μM.
The compounds can be split into two groups, based on their selectivity and their chemical 
structures; the first group contains the three tri-cyclic aromatic lactones and the other group 
contains 2BS4 by itself. None of these compounds inhibit the dehydrogenase activity of 
ALDH3A1, ALDH4A1, or ALDH5A1 at the concentrations tested. 2CB5, 2P3, and 2P4 
inhibit the activity of ALDH2 >80% at 10 μM. These compounds also inhibit the activity of 
ALDH1A1, ALDH1A2, ALDH1A3, and ALDH1B1, albeit less so than ALDH2. 2P4 does 
not substantially inhibit ALDH1A1 suggesting the length of the alkyl chain proximal to the 
carbonyl of the lactone is important for the inhibition of ALDH1A1. A compound with a 
shorter methyl chain (2P4) does not inhibit ALDH1A1 whereas compounds with longer 
propyl chains (2CB5 and 2P3) do inhibit ALDH1A1. This finding is consistent with the 
larger substrate binding channel found in the ALDH1A1 isoenzyme. Additionally, the 
shorter methyl chain of 2P4 appears to limit the inhibitory potency of the compound to all of 
the ALDH1/2 isoenzymes, as 2P4 shows less inhibition compared to 2P3 for all of the 
ALDH1/2 isoenzymes, which may relate to the largely hydrophobic substrate channels 
found in all of these isoenzymes. Comparing the action of 2CB5 and 2P3, the methyl chain 
proximal to the furan oxygen appears to play a role in the extent of inhibition toward these 
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isoenzymes. For each of the ALDH1/2 isozymes 2P3 inhibits greater than 2CB5. However, 
2P4, which shares the methyl chain proximal to the furan oxygen, shows less inhibition than 
2CB5 which lacks this particular methyl chain. This highlights the relative importance of the 
two alkyl chains which differ between these three compounds. It appears that increased 
hydrophobic interactions from the alkyl chains lead to more effective inhibition, as the 
compound with the most and longest alkyl chains (2P3) is the only compound of the three to 
inhibit each ALDH1A and ALDH1B member by at least 60%. 2BS4 inhibits ALDH2 
similar to 2CB5 and 2P3, but did not inhibit the activity of any other isoenzyme tested, 
making it the most selective compound of the four. However, 2BS4 is an ester and may be a 
competitive substrate for the esterase reaction of ALDH2, which would also compete with 
aldehyde oxidation since the same active site residues catalyze both reactions. To help 
determine how 2BS4 may be acting, the effect of 2-[(4-methyl-2-oxo-2H-chromen-7-
yl)oxy]propanoic acid (the free acid form of 2BS4) and 4-methyl-7-[(3-oxobutan-2-
yl)oxy]-2H-chromen-2-one (the methyl ketone of 2BS4) on the oxidation of 
propionaldehyde by ALDH2 was examined. Neither the free acid nor the terminal ketone 
analogs inhibited ALDH2, suggesting that the ester group itself, and not the carbonyl, is 
important for the inhibition of ALDH2. The lack of inhibition by the free acid is consistent 
with the fact that acid products are generally not inhibitory for most ALDH2/substrate 
combinations. In addition, pre-incubation of 2BS4 with ALDH2 for up to sixty minutes 
showed no evidence of a time-dependent mechanism of inhibition and no time-dependent 
change to the apparent IC50 for 2BS4 inhibition of ALDH2 (data not shown), suggesting 
that if hydrolysis is occurring it is slow relative to para-nitrophenylacetate hydrolysis or 
propionaldehyde oxidation.
4 Conclusion
The aromatic lactones identified by this screen are potent (2P4 Ki ≈ 35 nM for ALDH2) 
inhibitors of the ALDH1/2 isoenzymes. These compounds, upon further development, could 
be used to better determine the functions of each isoenzyme. These compounds also have 
therapeutic potential as inhibitors of the ALDH1/2 family of enzymes have medicinal 
applications as modulators of dopamine metabolism, antidipsotropic drugs, and as 
chemotherapy sensitizers. However, a strictly ALDH2-selective compound remains elusive 
as separating the inhibition of ALDH2 from the inhibition of ALDH1A1 has been difficult. 
Additionally, the effect of many currently used ALDH1A1 and ALDH2 inhibitors (for 
instance, disulfiram, daidzin or DEAB) on the related but lesser-studied ALDH1A2, 
ALDH1A3, and ALDH1B1 has not been fully examined. Two of the lactones reported here, 
2P4 and 2BS4, appear to inhibit ALDH2 without inhibiting ALDH1A1 achieving the 
separation in inhibition rarely seen in previous compounds. Future studies will include 
determining the dose-dependent effects of these four compounds on the various isoenzymes 
and determining the binding site of these compounds through x-ray crystallography to 
further the development of these aromatic lactones as ALDH1/2 inhibitors, with the hope 
that slight structural modifications will yield an ALDH1A1-selective or ALDH2-selective 
inhibitor.
Buchman et al. Page 7
Chem Biol Interact. Author manuscript; available in PMC 2016 June 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Acknowledgments
The authors would like to thank Cindy Morgan, Bibek Parajuli, and especially Lan Min Zhai for help with the 
production and purification of the various ALDH isozymes. The authors would also like to thank Lan Chen, PhD, 
and the Indiana University Chemical Genomics Core for providing access to their facilities to complete the high-
throughput screening and the chemical libraries and John Turchi, PhD, for use of the Cary Eclipse fluorimeter. This 
research was supported by NIH R01-AA018123. Cameron Buchman was supported by R13-AA023149 to present 
this work at the 17th Enzymology and Molecular Biology of Carbonyl Metabolism meeting held in Skytop, PA, 
USA.
References
1. Vasiliou V, Pappa A, Estey T. Role of human aldehyde dehydrogenases in endobiotic and 
xenobiotic metabolism. Drug metabolism reviews. 2004; 36:279–299. [PubMed: 15237855] 
2. Vasiliou V, Pappa A, Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic 
metabolism. Chemico-biological interactions. 2000; 129:1–19. [PubMed: 11154732] 
3. O’Brien PJ, Siraki AG, Shangari N. Aldehyde sources, metabolism, molecular toxicity mechanisms, 
and possible effects on human health. Critical reviews in toxicology. 2005; 35:609–662. [PubMed: 
16417045] 
4. Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the 
aldehyde dehydrogenase superfamily. Expert opinion on drug metabolism & toxicology. 2008; 
4:697–720. [PubMed: 18611112] 
5. Wong RH, Wang JD, Hsieh LL, Du CL, Cheng TJ. Effects on sister chromatid exchange frequency 
of aldehyde dehydrogenase 2 genotype and smoking in vinyl chloride workers. Mutation research. 
1998; 420:99–107. [PubMed: 9838066] 
6. Cheng G, Shi Y, Sturla SJ, Jalas JR, McIntee EJ, Villalta PW, Wang M, Hecht SS. Reactions of 
formaldehyde plus acetaldehyde with deoxyguanosine and DNA: formation of cyclic 
deoxyguanosine adducts and formaldehyde cross-links. Chemical research in toxicology. 2003; 
16:145–152. [PubMed: 12588185] 
7. Cho YJ, Wang H, Kozekov ID, Kurtz AJ, Jacob J, Voehler M, Smith J, Harris TM, Lloyd RS, Rizzo 
CJ, Stone MP. Stereospecific formation of interstrand carbinolamine DNA cross-links by 
crotonaldehyde- and acetaldehyde-derived alpha-CH3-gamma-OH-1,N2-propano-2′-
deoxyguanosine adducts in the 5′-CpG-3′ sequence. Chemical research in toxicology. 2006; 
19:195–208. [PubMed: 16485895] 
8. Kedishvili NY, Popov KM, Rougraff PM, Zhao Y, Crabb DW, Harris RA. CoA-dependent 
methylmalonate-semialdehyde dehydrogenase, a unique member of the aldehyde dehydrogenase 
superfamily. cDNA cloning, evolutionary relationships, and tissue distribution. The Journal of 
biological chemistry. 1992; 267:19724–19729. [PubMed: 1527093] 
9. Vasiliou V, Bairoch A, Tipton KF, Nebert DW. Eukaryotic aldehyde dehydrogenase (ALDH) genes: 
human polymorphisms, and recommended nomenclature based on divergent evolution and 
chromosomal mapping. Pharmacogenetics. 1999; 9:421–434. [PubMed: 10780262] 
10. Rizzo WB, Carney G. Sjogren-Larsson syndrome: diversity of mutations and polymorphisms in the 
fatty aldehyde dehydrogenase gene (ALDH3A2). Human mutation. 2005; 26:1–10. [PubMed: 
15931689] 
11. Vasiliou V, Pappa A. Polymorphisms of human aldehyde dehydrogenases. Consequences for drug 
metabolism and disease. Pharmacology. 2000; 61:192–198. [PubMed: 10971205] 
12. Geraghty MT, Vaughn D, Nicholson AJ, Lin WW, Jimenez-Sanchez G, Obie C, Flynn MP, Valle 
D, Hu CA. Mutations in the Delta1-pyrroline 5-carboxylate dehydrogenase gene cause type II 
hyperprolinemia. Human molecular genetics. 1998; 7:1411–1415. [PubMed: 9700195] 
13. Parajuli B, Kimble-Hill AC, Khanna M, Ivanova Y, Meroueh S, Hurley TD. Discovery of novel 
regulators of aldehyde dehydrogenase isoenzymes. Chemico-biological interactions. 2011; 
191:153–158. [PubMed: 21349255] 
14. Kimble-Hill AC, Parajuli B, Chen CH, Mochly-Rosen D, Hurley TD. Development of selective 
inhibitors for aldehyde dehydrogenases based on substituted indole-2,3-diones. Journal of 
medicinal chemistry. 2014; 57:714–722. [PubMed: 24444054] 
Buchman et al. Page 8
Chem Biol Interact. Author manuscript; available in PMC 2016 June 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
15. Parajuli B, Georgiadis TM, Fishel ML, Hurley TD. Development of selective inhibitors for human 
aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide 
cytotoxicity. Chembiochem : a European journal of chemical biology. 2014; 15:701–712. 
[PubMed: 24677340] 
16. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer 
research. 1984; 44:5156–5160. [PubMed: 6488175] 
17. Sreerama L, Sladek NE. Identification and characterization of a novel class 3 aldehyde 
dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting 
oxazaphosphorine-specific acquired resistance. Biochemical pharmacology. 1993; 45:2487–2505. 
[PubMed: 8328987] 
18. Moreb JS, Mohuczy D, Ostmark B, Zucali JR. RNAi-mediated knockdown of aldehyde 
dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the 
resistance against 4-hydroperoxycyclophosphamide. Cancer chemotherapy and pharmacology. 
2007; 59:127–136. [PubMed: 16614850] 
19. Chen Y, Orlicky DJ, Matsumoto A, Singh S, Thompson DC, Vasiliou V. Aldehyde dehydrogenase 
1B1 (ALDH1B1) is a potential biomarker for human colon cancer. Biochemical and biophysical 
research communications. 2011; 405:173–179. [PubMed: 21216231] 
20. Duester G. Families of retinoid dehydrogenases regulating vitamin A function: production of 
visual pigment and retinoic acid. European journal of biochemistry / FEBS. 2000; 267:4315–4324. 
[PubMed: 10880953] 
21. Niederreither K, Subbarayan V, Dolle P, Chambon P. Embryonic retinoic acid synthesis is 
essential for early mouse post-implantation development. Nature genetics. 1999; 21:444–448. 
[PubMed: 10192400] 
22. Dupe V, Matt N, Garnier JM, Chambon P, Mark M, Ghyselinck NB. A newborn lethal defect due 
to inactivation of retinaldehyde dehydrogenase type 3 is prevented by maternal retinoic acid 
treatment. Proceedings of the National Academy of Sciences of the United States of America. 
2003; 100:14036–14041. [PubMed: 14623956] 
23. Klyosov AA, Rashkovetsky LG, Tahir MK, Keung WM. Possible role of liver cytosolic and 
mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism. Biochemistry. 1996; 
35:4445–4456. [PubMed: 8605194] 
24. Farres J, Wang X, Takahashi K, Cunningham SJ, Wang TT, Weiner H. Effects of changing 
glutamate 487 to lysine in rat and human liver mitochondrial aldehyde dehydrogenase. A model to 
study human (Oriental type) class 2 aldehyde dehydrogenase. The Journal of biological chemistry. 
1994; 269:13854–13860. [PubMed: 7910607] 
25. Ueshima Y, Matsuda Y, Tsutsumi M, Takada A. Role of the aldehyde dehydrogenase-1 isozyme in 
the metabolism of acetaldehyde. Alcohol and alcoholism. 1993; 1B:15–19. [PubMed: 8003124] 
26. Stewart MJ, Malek K, Xiao Q, Dipple KM, Crabb DW. The novel aldehyde dehydrogenase gene, 
ALDH5, encodes an active aldehyde dehydrogenase enzyme. Biochemical and biophysical 
research communications. 1995; 211:144–151. [PubMed: 7779080] 
27. Marchitti SA, Deitrich RA, Vasiliou V. Neurotoxicity and metabolism of the catecholamine-
derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of 
aldehyde dehydrogenase. Pharmacological reviews. 2007; 59:125–150. [PubMed: 17379813] 
28. Mayer B, Beretta M. The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views 
and troubles. British journal of pharmacology. 2008; 155:170–184. [PubMed: 18574453] 
29. Hammen PK, Allali-Hassani A, Hallenga K, Hurley TD, Weiner H. Multiple conformations of 
NAD and NADH when bound to human cytosolic and mitochondrial aldehyde dehydrogenase. 
Biochemistry. 2002; 41:7156–7168. [PubMed: 12033950] 
30. Xiao T, Zhang M, Ansari N. Studies on aldehyde dehydrogenase 1(ALDH1A1), a crucial enzyme 
in maintaining the lens clarity under oxidative stress. Invest Ophth Vis Sci. 2005; 46
31. Wang X, Penzes P, Napoli JL. Cloning of a cDNA encoding an aldehyde dehydrogenase and its 
expression in Escherichia coli. Recognition of retinal as substrate. The Journal of biological 
chemistry. 1996; 271:16288–16293. [PubMed: 8663198] 
32. Stagos D, Chen Y, Brocker C, Donald E, Jackson BC, Orlicky DJ, Thompson DC, Vasiliou V. 
Aldehyde dehydrogenase 1B1: molecular cloning and characterization of a novel mitochondrial 
Buchman et al. Page 9
Chem Biol Interact. Author manuscript; available in PMC 2016 June 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
acetaldehyde-metabolizing enzyme. Drug metabolism and disposition: the biological fate of 
chemicals. 2010; 38:1679–1687. [PubMed: 20616185] 
33. Forte-McRobbie CM, Pietruszko R. Purification and characterization of human liver “high Km” 
aldehyde dehydrogenase and its identification as glutamic gamma-semialdehyde dehydrogenase. 
The Journal of biological chemistry. 1986; 261:2154–2163. [PubMed: 3944130] 
34. Ryzlak MT, Pietruszko R. Human brain glyceraldehyde-3-phosphate dehydrogenase, succinic 
semialdehyde dehydrogenase and aldehyde dehydrogenase isozymes: substrate specificity and 
sensitivity to disulfiram. Alcoholism, clinical and experimental research. 1989; 13:755–761.
35. Pappa A, Estey T, Manzer R, Brown D, Vasiliou V. Human aldehyde dehydrogenase 3A1 
(ALDH3A1): biochemical characterization and immunohistochemical localization in the cornea. 
The Biochemical journal. 2003; 376:615–623. [PubMed: 12943535] 
36. Klyosov AA. Kinetics and specificity of human liver aldehyde dehydrogenases toward aliphatic, 
aromatic, and fused polycyclic aldehydes. Biochemistry. 1996; 35:4457–4467. [PubMed: 
8605195] 
Buchman et al. Page 10
Chem Biol Interact. Author manuscript; available in PMC 2016 June 05.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Highlights
• High-thoughput screening identified a novel class of ALDH1/2-directed 
inhibitors.
• This class shares an aromatic lactone as a structural feature.
• Two lactones appear to be selective for ALDH2 versus ALDH1A1.
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Figure 1. 
A) Primary screen results for the 53 lead compounds. The esterase activity of ALDH2 with 
10 μM compound present was compared to the activity of ALDH2 in the absence of 
compound (- control). Selection criteria was either >130% activity or <65% activity. The 
positive control was 100 μM daidzin. B) Effect of the 53 lead compounds on the 
dehydrogenase activity of ALDH2. The oxidation of propionaldehyde by ALDH2 with 10 
μM compound present was compared to the activity of ALDH2 in the absence of compound. 
Value is an average of 2 trials.
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Figure 2. 
A) Structures of the aromatic lactones. B) Lineweaver-Burk representation of the fit to the 
tight binding mixed-type non-competitive inhibition equation for 2P4 versus varying 
propionaldehyde concentrations with ALDH2. Ki, Km, and α values are presented with 
standard error. The plot is a representative single experiment from one of four independent 
experiments. C) % Dehydrogenase activity for ALDH2, ALDH1B1, ALDH1A1, 
ALDH1A2, ALDH1A3, ALDH3A1, ALDH4A1, and ALDH5A1 in the presence of 10 μM 
compound. Value is the average of at least three independent trials (n≥3) with standard 
error, except for the measurement of ALDH1B1 activity with 2P4 (n=2).
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Table 1
Initial selectivity results for the most selective compounds. Listed is the dehydrogenase activity of ALDH2, 
ALDH1A1, and ALDH3A1 in the presence of 10 μM compound as the percent activity compared to the 
reaction without compound present.
Compound ALDH2 ALDH1A1* ALDH3A1
P0038D18 1.5 40.8 77.2
P0097G13 4.7 73.5 61.3
P0038B18 7.6 58.6 87.6
P0008L19 10.3 82.8 94.5
P0024N09 16.6 6.1 6.1
P0027H05 19.5 88.0 82.4
P0038F16 20.7 89.3 87.8
P0019E01 40.1 158.9 85
P0030J09 41.6 69.7 77.3
P0143B06 66.9 29.1 45.4
P0066I15 70.6 2.0 N/M
P0146I21 124 126.9 119.7
*N121S polymorphism
N/M = Not Measured
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